Neuroendocrine Tumors Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Neuroendocrine Tumors Market is segmented By Clinical Development Phase (Late-stage Products (Phase III), Mid-stage Products (Phase II), Early-stage P....
Neuroendocrine Tumors Market Size
Market Size in USD
CAGR6.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.2% |
| Market Concentration | High |
| Major Players | RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Neotropix, Inc. |
please let us know !
Neuroendocrine Tumors Market Analysis
The Global Neuroendocrine Tumors Market is estimated to be valued at USD 4.8 billion in 2024 and is expected to reach USD 7.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Advancements in diagnostic techniques and the development of new targeted and combination therapies are fueling market growth. The market is witnessing positive trends with the rising prevalence of neuroendocrine tumors worldwide. Furthermore, increasing research activities for biomarker development, targeted drug delivery, and development of combination therapy regimens for treatment are expected to provide lucrative opportunities for market players over the forecast period.